

HB5268



101ST GENERAL ASSEMBLY

State of Illinois

2019 and 2020

HB5268

by Rep. John Connor

SYNOPSIS AS INTRODUCED:

720 ILCS 570/204

from Ch. 56 1/2, par. 1204

Amends the Illinois Controlled Substances Act. Includes various fentanyl analogs in the list of Schedule I controlled substances.

LRB101 19113 RLC 68576 b

CORRECTIONAL
BUDGET AND
IMPACT NOTE ACT
MAY APPLY

A BILL FOR

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Section 204 as follows:

6 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

7 Sec. 204. (a) The controlled substances listed in this
8 Section are included in Schedule I.

9 (b) Unless specifically excepted or unless listed in
10 another schedule, any of the following opiates, including their
11 isomers, esters, ethers, salts, and salts of isomers, esters,
12 and ethers, whenever the existence of such isomers, esters,
13 ethers and salts is possible within the specific chemical
14 designation:

15 (1) Acetylmethadol;

16 (1.1) Acetyl-alpha-methylfentanyl

17 (N-[1-(1-methyl-2-phenethyl)-

18 4-piperidinyl]-N-phenylacetamide);

19 (2) Allylprodine;

20 (3) Alphacetylmethadol, except

21 levo-alphacetylmethadol (also known as levo-alpha-
22 acetylmethadol, levomethadyl acetate, or LAAM);

23 (4) Alphameprodine;

- 1 (5) Alphamethadol;
- 2 (6) Alpha-methylfentanyl
- 3 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
- 4 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
- 5 propanilido) piperidine;
- 6 (6.1) Alpha-methylthiofentanyl
- 7 (N-[1-methyl-2-(2-thienyl) ethyl-
- 8 4-piperidinyl]-N-phenylpropanamide);
- 9 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
- 10 (7.1) PEPAP
- 11 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 12 (8) Benzethidine;
- 13 (9) Betacetylmethadol;
- 14 (9.1) Beta-hydroxyfentanyl
- 15 (N-[1-(2-hydroxy-2-phenethyl)-
- 16 4-piperidinyl]-N-phenylpropanamide);
- 17 (10) Betameprodine;
- 18 (11) Betamethadol;
- 19 (12) Betaprodine;
- 20 (13) Clonitazene;
- 21 (14) Dextromoramide;
- 22 (15) Diampromide;
- 23 (16) Diethylthiambutene;
- 24 (17) Difenoazin;
- 25 (18) Dimenoxadol;
- 26 (19) Dimepheptanol;

- 1 (20) Dimethylthiambutene;
- 2 (21) Dioxaphetylbutyrate;
- 3 (22) Dipipanone;
- 4 (23) Ethylmethylthiambutene;
- 5 (24) Etonitazene;
- 6 (25) Etoperidone;
- 7 (26) Furethidine;
- 8 (27) Hydroxypethidine;
- 9 (28) Ketobemidone;
- 10 (29) Levomoramide;
- 11 (30) Levophenacymorphan;
- 12 (31) 3-Methylfentanyl
- 13 (N-[3-methyl-1-(2-phenylethyl)-
- 14 4-piperidyl]-N-phenylpropanamide);
- 15 (31.1) 3-Methylthiofentanyl
- 16 (N-[(3-methyl-1-(2-thienyl)ethyl-
- 17 4-piperidinyl]-N-phenylpropanamide);
- 18 (32) Morpheridine;
- 19 (33) Noracymethadol;
- 20 (34) Norlevorphanol;
- 21 (35) Normethadone;
- 22 (36) Norpipanone;
- 23 (36.1) Para-fluorofentanyl
- 24 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
- 25 4-piperidinyl]propanamide);
- 26 (37) Phenadoxone;

- 1 (38) Phenampromide;
- 2 (39) Phenomorphan;
- 3 (40) Phenoperidine;
- 4 (41) Piritramide;
- 5 (42) Proheptazine;
- 6 (43) Properidine;
- 7 (44) Propiram;
- 8 (45) Racemoramide;
- 9 (45.1) Thiofentanyl
- 10 (N-phenyl-N-[1-(2-thienyl)ethyl-
- 11 4-piperidinyl]-propanamide);
- 12 (46) Tilidine;
- 13 (47) Trimeperidine;
- 14 (48) Beta-hydroxy-3-methylfentanyl (other name:
- 15 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
- 16 N-phenylpropanamide);
- 17 (49) Furanyl fentanyl (FU-F);
- 18 (50) Butyryl fentanyl;
- 19 (51) Valeryl fentanyl;
- 20 (52) Acetyl fentanyl;
- 21 (53) Beta-hydroxy-thiofentanyl;
- 22 (54) 3,4-dichloro-N-[2-
- 23 (dimethylamino)cyclohexyl]-N-
- 24 methylbenzamide (U-47700);
- 25 (55) 4-chloro-N-[1-[2-
- 26 (4-nitrophenyl)ethyl]-2-piperidinylidene]-

1 benzenesulfonamide (W-18);

2 (56) 4-chloro-N-[1-(2-phenylethyl)

3 -2-piperidinylidene]-benzenesulfonamide (W-15);

4 (57) acrylfentanyl (acryloylfentanyl);~~;~~

5 (b-5) Fentanyl analogs, including any compound, except
6 compounds scheduled elsewhere in this Act, structurally
7 derived from fentanyl by replacement of the phenyl portion of
8 the phenethyl group by any monocycle whether or not further
9 substituted in or on the monocycle; by substitution in or on
10 the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halo,
11 haloalkyl, amino or nitro groups; by substitution in or on the
12 piperidine ring with alkyl, alkenyl, alkoxy, ester, ether,
13 hydroxy, halo, haloalkyl, amino or nitro groups; by replacement
14 of the aniline ring with any aromatic monocycle whether or not
15 further substituted in or on the aromatic monocycle; by
16 replacement of the N-propionyl group by another acyl group; or
17 by any combination of these modifications. Substances
18 specified under this subsection include all of the following:

19 (1) Cyclopentyl fentanyl

20 (N-(1-phenethylpiperidin-4-yl)-N-
21 phenylcyclopentanecarboxamide);

22 (2) 4-fluorobutyryl fentanyl (N-
23 (4-fluorophenyl)-N-[1-(2-phenylethyl)
24 piperidin-4-yl]-butyramide);

25 (3) Isobutyryl fentanyl (2-methyl-N-phenyl-
26 N-[1-(2-phenylethyl)piperidin-4-yl]

1 -propanamide);

2 (4) Methoxyacetyl fentanyl (2-methoxy-
3 N-phenyl-N-[1-(2-phenylethyl)piperidin
4 -4-yl]-acetamide);

5 (5) 3-methylbutyryl fentanyl (N-
6 [3-methyl-1-(2-phenylethyl)piperidin
7 -4-yl]-N-phenylbutyramide);

8 (6) 4-methoxybutyryl fentanyl (N-
9 (4-methoxyphenyl)-N-(1-phenethylpiperidin
10 -4-yl)butyramide);

11 (7) Ocfentanil (N-(2-fluorophenyl)-2-
12 methoxy-N-[1-(2-phenylethyl)piperidin
13 -4-yl]-acetamide);

14 (8) Tetrahydrofuran fentanyl (N-
15 (1-phenethylpiperidin-4-yl)-N-
16 phenyltetrahydrofuran-2-carboxamide);

17 (9) Valeryl fentanyl (N-phenyl-N-
18 [1-(2-phenylethyl)piperidin-4-yl]pentanamide).

19 (c) Unless specifically excepted or unless listed in
20 another schedule, any of the following opium derivatives, its
21 salts, isomers and salts of isomers, whenever the existence of
22 such salts, isomers and salts of isomers is possible within the
23 specific chemical designation:

24 (1) Acetorphine;

25 (2) Acetyldihydrocodeine;

26 (3) Benzylmorphine;

- 1 (4) Codeine methylbromide;
- 2 (5) Codeine-N-Oxide;
- 3 (6) Cyprenorphine;
- 4 (7) Desomorphine;
- 5 (8) Diacetyldihydromorphine (Dihydroheroin);
- 6 (9) Dihydromorphine;
- 7 (10) Drotebanol;
- 8 (11) Etorphine (except hydrochloride salt);
- 9 (12) Heroin;
- 10 (13) Hydromorphenol;
- 11 (14) Methyldesorphine;
- 12 (15) Methyldihydromorphine;
- 13 (16) Morphine methylbromide;
- 14 (17) Morphine methylsulfonate;
- 15 (18) Morphine-N-Oxide;
- 16 (19) Myrophine;
- 17 (20) Nicocodeine;
- 18 (21) Nicomorphine;
- 19 (22) Normorphine;
- 20 (23) Pholcodine;
- 21 (24) Thebacon.

22 (d) Unless specifically excepted or unless listed in
23 another schedule, any material, compound, mixture, or
24 preparation which contains any quantity of the following
25 hallucinogenic substances, or which contains any of its salts,
26 isomers and salts of isomers, whenever the existence of such

1 salts, isomers, and salts of isomers is possible within the
2 specific chemical designation (for the purposes of this
3 paragraph only, the term "isomer" includes the optical,
4 position and geometric isomers):

5 (1) 3,4-methylenedioxyamphetamine

6 (alpha-methyl, 3,4-methylenedioxyphenethylamine,
7 methylenedioxyamphetamine, MDA);

8 (1.1) Alpha-ethyltryptamine

9 (some trade or other names: etryptamine;
10 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
11 3-(2-aminobutyl)indole; a-ET; and AET);

12 (2) 3,4-methylenedioxymethamphetamine (MDMA);

13 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
14 (also known as: N-ethyl-alpha-methyl-
15 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
16 and MDEA);

17 (2.2) N-Benzylpiperazine (BZP);

18 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);

19 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);

20 (4) 3,4,5-trimethoxyamphetamine (TMA);

21 (5) (Blank);

22 (6) Diethyltryptamine (DET);

23 (7) Dimethyltryptamine (DMT);

24 (7.1) 5-Methoxy-diallyltryptamine;

25 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);

26 (9) Ibogaine (some trade and other names:

1 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
2 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
3 indole; Tabernanthe iboga);

4 (10) Lysergic acid diethylamide;

5 (10.1) Salvinorin A;

6 (10.5) Salvia divinorum (meaning all parts of the plant
7 presently classified botanically as Salvia divinorum,
8 whether growing or not, the seeds thereof, any extract from
9 any part of that plant, and every compound, manufacture,
10 salts, isomers, and salts of isomers whenever the existence
11 of such salts, isomers, and salts of isomers is possible
12 within the specific chemical designation, derivative,
13 mixture, or preparation of that plant, its seeds or
14 extracts);

15 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

16 (12) Peyote (meaning all parts of the plant presently
17 classified botanically as Lophophora williamsii Lemaire,
18 whether growing or not, the seeds thereof, any extract from
19 any part of that plant, and every compound, manufacture,
20 salts, derivative, mixture, or preparation of that plant,
21 its seeds or extracts);

22 (13) N-ethyl-3-piperidyl benzilate (JB 318);

23 (14) N-methyl-3-piperidyl benzilate;

24 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
25 (also known as N-hydroxy-alpha-methyl-
26 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

- 1 (15) Parahexyl; some trade or other names:
2 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
3 dibenzo (b,d) pyran; Synhexyl;
- 4 (16) Psilocybin;
- 5 (17) Psilocyn;
- 6 (18) Alpha-methyltryptamine (AMT);
- 7 (19) 2,5-dimethoxyamphetamine
8 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
- 9 (20) 4-bromo-2,5-dimethoxyamphetamine
10 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
11 4-bromo-2,5-DMA);
- 12 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
13 Some trade or other names: 2-(4-bromo-
14 2,5-dimethoxyphenyl)-1-aminoethane;
15 alpha-desmethyl DOB, 2CB, Nexus;
- 16 (21) 4-methoxyamphetamine
17 (4-methoxy-alpha-methylphenethylamine;
18 paramethoxyamphetamine; PMA);
- 19 (22) (Blank);
- 20 (23) Ethylamine analog of phencyclidine.
21 Some trade or other names:
22 N-ethyl-1-phenylcyclohexylamine,
23 (1-phenylcyclohexyl) ethylamine,
24 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
- 25 (24) Pyrrolidine analog of phencyclidine. Some trade
26 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,

1 PHP;

2 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;

3 (26) 2,5-dimethoxy-4-ethylamphetamine

4 (another name: DOET);

5 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

6 (another name: TCPy);

7 (28) (Blank);

8 (29) Thiophene analog of phencyclidine (some trade

9 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;

10 2-thienyl analog of phencyclidine; TCP; TCP);

11 (29.1) Benzothiophene analog of phencyclidine. Some

12 trade or other names: BTCP or benocyclidine;

13 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);

14 (30) Bufotenine (some trade or other names:

15 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

16 3-(2-dimethylaminoethyl)-5-indolol;

17 5-hydroxy-N,N-dimethyltryptamine;

18 N,N-dimethylserotonin; mappine);

19 (31) (Blank);

20 (32) (Blank);

21 (33) (Blank);

22 (34) (Blank);

23 (34.5) (Blank);

24 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-

25 (2-methyloctan-2-yl)-6a,7,

26 10,10a-tetrahydrobenzo[c]chromen-1-ol

1 Some trade or other names: HU-210;

2 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
3 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
4 tetrahydrobenzo[c]chromen-1-ol, its isomers,
5 salts, and salts of isomers; Some trade or other
6 names: HU-210, Dexanabinol;

7 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
8 6,6-dimethyl-3-(2-methyloctan-2-yl)-
9 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

10 Some trade or other names: HU-211;

11 (37) (Blank);

12 (38) (Blank);

13 (39) (Blank);

14 (40) (Blank);

15 (41) (Blank);

16 (42) Any compound structurally derived from
17 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane
18 by substitution at the nitrogen atom of the indole ring by
19 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
20 cycloalkylethyl, aryl halide, alkyl aryl halide,
21 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl whether or not further substituted
23 in the indole ring to any extent, whether or not
24 substituted in the naphthyl ring to any extent. Examples of
25 this structural class include, but are not limited to,
26 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;

1 (43) Any compound structurally derived from
2 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
3 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
5 halide, 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further substituted
7 in the pyrrole ring to any extent, whether or not
8 substituted in the naphthyl ring to any extent. Examples of
9 this structural class include, but are not limited to,
10 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

11 (44) Any compound structurally derived from
12 1-(1-naphthylmethyl)indene by substitution at the
13 3-position of the indene ring by alkyl, haloalkyl, alkenyl,
14 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
15 halide, 1-(N-methyl-2-piperidinyl)methyl, or
16 2-(4-morpholinyl)ethyl whether or not further substituted
17 in the indene ring to any extent, whether or not
18 substituted in the naphthyl ring to any extent. Examples of
19 this structural class include, but are not limited to,
20 JWH-176;

21 (45) Any compound structurally derived from
22 3-phenylacetylindole by substitution at the nitrogen atom
23 of the indole ring with alkyl, haloalkyl, alkenyl,
24 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
25 halide, 1-(N-methyl-2-piperidinyl)methyl, or
26 2-(4-morpholinyl)ethyl, whether or not further substituted

1 in the indole ring to any extent, whether or not
2 substituted in the phenyl ring to any extent. Examples of
3 this structural class include, but are not limited to,
4 JWH-167, JWH-250, JWH-251, and RCS-8;

5 (46) Any compound structurally derived from
6 2-(3-hydroxycyclohexyl)phenol by substitution at the
7 5-position of the phenolic ring by alkyl, haloalkyl,
8 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
9 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
10 2-(4-morpholinyl)ethyl, whether or not substituted in the
11 cyclohexyl ring to any extent. Examples of this structural
12 class include, but are not limited to, CP 47, 497 and its
13 C8 homologue (cannabicyclohexanol);

14 (46.1) Any compound structurally derived from
15 3-(benzoyl) indole with substitution at the nitrogen atom
16 of the indole ring by an alkyl, haloalkyl, alkenyl,
17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18 halide, 1-(N-methyl-2-piperidinyl)methyl, or
19 2-(4-morpholinyl)ethyl group whether or not further
20 substituted in the indole ring to any extent and whether or
21 not substituted in the phenyl ring to any extent. Examples
22 of this structural class include, but are not limited to,
23 AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and
24 RCS-4;

25 (47) (Blank);

26 (48) (Blank);

1 (49) (Blank);

2 (50) (Blank);

3 (51) (Blank);

4 (52) (Blank);

5 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.

6 Some trade or other names: 2C-T-7;

7 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some trade

8 or other names: 2C-E;

9 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some

10 trade or other names: 2C-D;

11 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some

12 trade or other names: 2C-C;

13 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade

14 or other names: 2C-I;

15 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some

16 trade or other names: 2C-T-2;

17 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.

18 Some trade or other names: 2C-T-4;

19 (53.7) 2,5-dimethoxyphenethylamine. Some trade or

20 other names: 2C-H;

21 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some trade

22 or other names: 2C-N;

23 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some

24 trade or other names: 2C-P;

25 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. Some

26 trade or other names: 2C-G;

1 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
2 phenethylamine referred to in subparagraphs (20.1), (53),
3 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
4 (53.8), (53.9), and (53.10) including, but not limited to,
5 25I-NBOMe and 25C-NBOMe;

6 (54) 5-Methoxy-N,N-diisopropyltryptamine;

7 (55) (Blank);

8 (56) (Blank);

9 (57) (Blank);

10 (58) (Blank);

11 (59) 3-cyclopropoylindole with substitution at the
12 nitrogen atom of the indole ring by alkyl, haloalkyl,
13 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
14 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further substituted
16 on the indole ring to any extent, whether or not
17 substituted on the cyclopropyl ring to any extent:
18 including, but not limited to, XLR11, UR144, FUB-144;

19 (60) 3-adamantoylindole with substitution at the
20 nitrogen atom of the indole ring by alkyl, haloalkyl,
21 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
22 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
23 2-(4-morpholinyl)ethyl, whether or not further substituted
24 on the indole ring to any extent, whether or not
25 substituted on the adamantyl ring to any extent: including,
26 but not limited to, AB-001;

1 (61) N-(adamantyl)-indole-3-carboxamide with
2 substitution at the nitrogen atom of the indole ring by
3 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
4 cycloalkylethyl, aryl halide, alkyl aryl halide,
5 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further substituted
7 on the indole ring to any extent, whether or not
8 substituted on the adamantyl ring to any extent: including,
9 but not limited to, APICA/2NE-1, STS-135;

10 (62) N-(adamantyl)-indazole-3-carboxamide with
11 substitution at a nitrogen atom of the indazole ring by
12 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
13 cycloalkylethyl, aryl halide, alkyl aryl halide,
14 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further substituted
16 on the indazole ring to any extent, whether or not
17 substituted on the adamantyl ring to any extent: including,
18 but not limited to, AKB48, 5F-AKB48;

19 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
20 with substitution at the nitrogen atom of the indole ring
21 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
22 cycloalkylethyl, aryl halide, alkyl aryl halide,
23 1-(N-methyl-2-piperidinyl)methyl, or
24 2-(4-morpholinyl)ethyl, whether or not further substituted
25 on the indole ring to any extent, whether or not
26 substituted on the quinoline ring to any extent: including,

1 but not limited to, PB22, 5F-PB22, FUB-PB-22;

2 (64) 3-(1-naphthoyl)indazole with substitution at the
3 nitrogen atom of the indazole ring by alkyl, haloalkyl,
4 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
5 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further substituted
7 on the indazole ring to any extent, whether or not
8 substituted on the naphthyl ring to any extent: including,
9 but not limited to, THJ-018, THJ-2201;

10 (65) 2-(1-naphthoyl)benzimidazole with substitution at
11 the nitrogen atom of the benzimidazole ring by alkyl,
12 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
13 aryl halide, alkyl aryl halide,
14 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further substituted
16 on the benzimidazole ring to any extent, whether or not
17 substituted on the naphthyl ring to any extent: including,
18 but not limited to, FUBIMINA;

19 (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
20 3-carboxamide with substitution on the nitrogen atom of the
21 indazole ring by alkyl, haloalkyl, alkenyl,
22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
23 halide, 1-(N-methyl-2-piperidinyl)methyl, or
24 2-(4-morpholinyl)ethyl, whether or not further substituted
25 on the indazole ring to any extent: including, but not
26 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;

1 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
2 indazole-3-carboxamide with substitution on the nitrogen
3 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
5 halide, 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further substituted
7 on the indazole ring to any extent: including, but not
8 limited to, ADB-PINACA, ADB-FUBINACA;

9 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
10 indole-3-carboxamide with substitution on the nitrogen
11 atom of the indole ring by alkyl, haloalkyl, alkenyl,
12 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
13 halide, 1-(N-methyl-2-piperidinyl)methyl, or
14 2-(4-morpholinyl)ethyl, whether or not further substituted
15 on the indole ring to any extent: including, but not
16 limited to, ADBICA, 5F-ADBICA;

17 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
18 3-carboxamide with substitution on the nitrogen atom of the
19 indole ring by alkyl, haloalkyl, alkenyl,
20 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
21 halide, 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not further substituted
23 on the indole ring to any extent: including, but not
24 limited to, ABICA, 5F-ABICA;

25 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
26 methylbutanoate with substitution on the nitrogen atom of

1 the indazole ring by alkyl, haloalkyl, alkenyl,
2 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
3 halide, 1-(N-methyl-2-piperidinyl)methyl, or
4 2-(4-morpholinyl)ethyl, whether or not further substituted
5 on the indazole ring to any extent: including, but not
6 limited to, AMB, 5F-AMB;

7 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
8 dimethylbutanoate with substitution on the nitrogen atom
9 of the indazole ring by alkyl, haloalkyl, alkenyl,
10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11 halide, 1-(N-methyl-2-piperidinyl)methyl, or
12 2-(4-morpholinyl)ethyl, whether or not further substituted
13 on the indazole ring to any extent: including, but not
14 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

15 (72) Methyl 2-(1H-indole-3-carboxamido)-3-
16 methylbutanoate with substitution on the nitrogen atom of
17 the indole ring by alkyl, haloalkyl, alkenyl,
18 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
19 halide, 1-(N-methyl-2-piperidinyl)methyl, or
20 2-(4-morpholinyl)ethyl, whether or not further substituted
21 on the indazole ring to any extent: including, but not
22 limited to, MMB018, MMB2201, and AMB-CHMICA;

23 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
24 dimethylbutanoate with substitution on the nitrogen atom
25 of the indole ring by alkyl, haloalkyl, alkenyl,
26 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl

1 halide, 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl, whether or not further substituted
3 on the indazole ring to any extent: including, but not
4 limited to, MDMB-CHMICA;

5 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
6 indazole-3-carboxamide with substitution on the nitrogen
7 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
8 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
9 halide, 1-(N-methyl-2-piperidinyl)methyl, or
10 2-(4-morpholinyl)ethyl, whether or not further substituted
11 on the indazole ring to any extent: including, but not
12 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;

13 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
14 3-carboxamide with substitution on the nitrogen atom of the
15 indole ring by alkyl, haloalkyl, alkenyl,
16 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
17 halide, 1-(N-methyl-2-piperidinyl)methyl, or
18 2-(4-morpholinyl)ethyl, whether or not further substituted
19 on the indazole ring to any extent: including, but not
20 limited to, APP-PICA and 5-fluoro-APP-PICA;

21 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
22 4-AcO-DMT;

23 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
24 name 5-MeO-MIPT;

25 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);

26 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

- 1 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
2 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
3 (4-HO-MiPT);
4 (82) Fluorophenylpiperazine;
5 (83) Methoxetamine;
6 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
7 ethcathinone).

8 (e) Unless specifically excepted or unless listed in
9 another schedule, any material, compound, mixture, or
10 preparation which contains any quantity of the following
11 substances having a depressant effect on the central nervous
12 system, including its salts, isomers, and salts of isomers
13 whenever the existence of such salts, isomers, and salts of
14 isomers is possible within the specific chemical designation:

- 15 (1) mecloqualone;
16 (2) methaqualone; and
17 (3) gamma hydroxybutyric acid.

18 (f) Unless specifically excepted or unless listed in
19 another schedule, any material, compound, mixture, or
20 preparation which contains any quantity of the following
21 substances having a stimulant effect on the central nervous
22 system, including its salts, isomers, and salts of isomers:

- 23 (1) Fenethylamine;
24 (2) N-ethylamphetamine;
25 (3) Aminorex (some other names:
26 2-amino-5-phenyl-2-oxazoline; aminoxaphen;

1 4-5-dihydro-5-phenyl-2-oxazolamine) and its
2 salts, optical isomers, and salts of optical isomers;

3 (4) Methcathinone (some other names:
4 2-methylamino-1-phenylpropan-1-one;
5 Ephedrone; 2-(methylamino)-propiofenone;
6 alpha-(methylamino)propiofenone; N-methylcathinone;
7 methycathinone; Monomethylpropion; UR 1431) and its
8 salts, optical isomers, and salts of optical isomers;

9 (5) Cathinone (some trade or other names:
10 2-aminopropiofenone; alpha-aminopropiofenone;
11 2-amino-1-phenyl-propanone; norephedrone);

12 (6) N,N-dimethylamphetamine (also known as:
13 N,N-alpha-trimethyl-benzeneethanamine;
14 N,N-alpha-trimethylphenethylamine);

15 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
16 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);

17 (8) 3,4-Methylenedioxypropylamphetamine (MDPV);

18 (9) Halogenated amphetamines and
19 methamphetamines - any compound derived from either
20 amphetamine or methamphetamine through the substitution
21 of a halogen on the phenyl ring, including, but not
22 limited to, 2-fluoroamphetamine, 3-
23 fluoroamphetamine and 4-fluoroamphetamine;

24 (10) Aminopropylbenzofuran (APB):
25 including 4-(2-Aminopropyl) benzofuran, 5-
26 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)

1 benzofuran, and 7-(2-Aminopropyl) benzofuran;

2 (11) Aminopropyldihydrobenzofuran (APDB):
3 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
4 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
5 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
6 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;

7 (12) Methylaminopropylbenzofuran
8 (MAPB): including 4-(2-methylaminopropyl)
9 benzofuran, 5-(2-methylaminopropyl)benzofuran,
10 6-(2-methylaminopropyl)benzofuran
11 and 7-(2-methylaminopropyl)benzofuran.

12 (g) Temporary listing of substances subject to emergency
13 scheduling. Any material, compound, mixture, or preparation
14 that contains any quantity of the following substances:

15 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
16 (benzylfentanyl), its optical isomers, isomers, salts, and
17 salts of isomers;

18 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
19 phenylpropanamide (thenylfentanyl), its optical isomers,
20 salts, and salts of isomers.

21 (h) Synthetic cathinones. Unless specifically excepted,
22 any chemical compound which is not approved by the United
23 States Food and Drug Administration or, if approved, is not
24 dispensed or possessed in accordance with State or federal law,
25 not including bupropion, structurally derived from
26 2-aminopropan-1-one by substitution at the 1-position with

1 either phenyl, naphthyl, or thiophene ring systems, whether or
2 not the compound is further modified in one or more of the
3 following ways:

4 (1) by substitution in the ring system to any extent
5 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
6 halide substituents, whether or not further substituted in
7 the ring system by one or more other univalent
8 substituents. Examples of this class include, but are not
9 limited to, 3,4-Methylenedioxcathinone (bk-MDA);

10 (2) by substitution at the 3-position with an acyclic
11 alkyl substituent. Examples of this class include, but are
12 not limited to, 2-methylamino-1-phenylbutan-1-one
13 (buphedrone); or

14 (3) by substitution at the 2-amino nitrogen atom with
15 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
16 inclusion of the 2-amino nitrogen atom in a cyclic
17 structure. Examples of this class include, but are not
18 limited to, Dimethylcathinone, Ethcathinone, and
19 α -Pyrrolidinopropiophenone (α -PPP); or

20 Any other synthetic cathinone which is not approved by the
21 United States Food and Drug Administration or, if approved, is
22 not dispensed or possessed in accordance with State or federal
23 law.

24 (i) Synthetic cannabinoids or piperazines. Any synthetic
25 cannabinoid or piperazine which is not approved by the United
26 States Food and Drug Administration or, if approved, which is

1 not dispensed or possessed in accordance with State and federal
2 law.

3 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
4 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
5 8-14-18.)